Theratechnologies Inc. (NASDAQ:THTX) Short Interest Update

Theratechnologies Inc. (NASDAQ:THTX) was the recipient of a large decline in short interest in the month of September. As of September 15th, there was short interest totalling 10,500 shares, a decline of 23.9% from the August 31st total of 13,800 shares. Based on an average daily trading volume, of 40,700 shares, the short-interest ratio is currently 0.3 days. Approximately 0.1% of the company’s stock are short sold.

Theratechnologies Stock Performance

Shares of THTX opened at $1.25 on Friday. The stock has a 50-day moving average price of $1.32 and a 200 day moving average price of $1.34. The company has a market capitalization of $57.48 million, a P/E ratio of -6.58 and a beta of 1.41. Theratechnologies has a one year low of $0.88 and a one year high of $2.58.

Theratechnologies (NASDAQ:THTX) last released its quarterly earnings data on Wednesday, July 10th. The company reported $0.02 earnings per share for the quarter, topping the consensus estimate of ($0.02) by $0.04. The business had revenue of $22.02 million for the quarter. During the same quarter last year, the business posted ($0.40) EPS. As a group, equities research analysts forecast that Theratechnologies will post -0.02 earnings per share for the current fiscal year.

About Theratechnologies

Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.